pU6-pegRNA-LRRK2-G2019S-3a
(Plasmid
#180432)
-
PurposeTransiently expressing a pegRNA to introduce LRRK2-G2019S mutation in human cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 180432 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepU6-pegRNA-GG-acceptor
-
Backbone manufacturerAddgene Plasmid #132777
- Backbone size w/o insert (bp) 3000
-
Vector typeMammalian Expression, CRISPR
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namencRNA targeting LRRK2-G2019S
-
Alt namePARK8; RIPK7; ROCO2; AURA17; DARDARIN
-
gRNA/shRNA sequencePBS9-RTT12: GATTGCAAAGATTGCTGACTAgttttAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGgtgcGCAATGCtGTAGTCAGCAATC
-
SpeciesH. sapiens (human)
-
Insert Size (bp)118
-
MutationLRRK2-G2019S
-
Entrez GeneLRRK2 (a.k.a. AURA17, DARDARIN, PARK8, RIPK7, ROCO2)
- Promoter U6
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BsaI (destroyed during cloning)
- 3′ cloning site BsaI (destroyed during cloning)
- 5′ sequencing primer ACTATCATATGCTTACCGTAAC (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pU6-pegRNA-LRRK2-G2019S-3a was a gift from Frank Soldner (Addgene plasmid # 180432 ; http://n2t.net/addgene:180432 ; RRID:Addgene_180432) -
For your References section:
Highly efficient generation of isogenic pluripotent stem cell models using prime editing. Li H, Busquets O, Verma Y, Syed KM, Kutnowski N, Pangilinan GR, Gilbert LA, Bateup HS, Rio DC, Hockemeyer D, Soldner F. Elife. 2022 Sep 7;11:e79208. doi: 10.7554/eLife.79208. 10.7554/eLife.79208 PubMed 36069759